Research
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f2023 (Published 16 April 2013) Cite this as: BMJ 2013;346:f2023
Data supplement
Web Extra
Extra material supplied by the author [posted as supplied]
Files in this Data Supplement:
- Data Supplement - Appendix 1: Flow chart of participants
- Data Supplement - Appendix 2: Validation of imputation approach and supplementary tables
Related articles
- Research Published: 14 September 2010; BMJ 341 doi:10.1136/bmj.c4521
- Research Published: 10 January 2018; BMJ 360 doi:10.1136/bmj.j5757
See more
- US women must be told breast density after mammogram, says FDABMJ September 18, 2024, 386 q2045; DOI: https://doi.org/10.1136/bmj.q2045
- Government considers outdoor smoking ban in EnglandBMJ August 30, 2024, 386 q1908; DOI: https://doi.org/10.1136/bmj.q1908
- US spends $43bn a year on cancer screeningBMJ August 12, 2024, 386 q1787; DOI: https://doi.org/10.1136/bmj.q1787
- Johnson & Johnson pays $700m to 42 US states to settle Baby Powder asbestos claimsBMJ June 26, 2024, 385 q1425; DOI: https://doi.org/10.1136/bmj.q1425
- Lib Dems launch “manifesto to save NHS” with pledges on GP access and cancerBMJ June 11, 2024, 385 q1288; DOI: https://doi.org/10.1136/bmj.q1288
Cited by...
- Genetically Adjusted PSA Levels for Prostate Cancer Screening
- Genetically Adjusted PSA Levels for Prostate Cancer Screening
- Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps
- Leveraging Genetic Determinants of Prostate-Specific Antigen Levels Towards Improving Prostate Cancer Screening
- Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program
- The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment
- Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial
- Age dependence of modern clinical risk groups for localized prostate cancer - a population-based study
- Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts
- Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening
- Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer
- Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening
- Prostate Cancer Early Detection, Version 2.2015
- The Case for Tailored Prostate Cancer Screening: An NCCN Perspective
- Recommendations on screening for prostate cancer with the prostate-specific antigen test
- Prostate Cancer Early Detection, Version 1.2014
- Still not enough evidence to support screening based on prostate specific antigen
- Focused PSA Screening Strategy, Based on Empirical Data